Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 29.8%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totaling 2,168,608 shares, a decline of 29.8% from the December 15th total of 3,088,368 shares. Based on an average daily volume of 269,707 shares, the short-interest ratio is presently 8.0 days. Approximately 4.5% of the shares of the company are sold short. Approximately 4.5% of the shares of the company are sold short. Based on an average daily volume of 269,707 shares, the short-interest ratio is presently 8.0 days.

Institutional Trading of Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Squarepoint Ops LLC lifted its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 328,794 shares of the company’s stock after purchasing an additional 93,338 shares during the quarter. Squarepoint Ops LLC owned about 0.63% of Xilio Therapeutics worth $277,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $2.00.

Xilio Therapeutics Price Performance

Shares of NASDAQ XLO remained flat at $0.64 during trading on Friday. 132,874 shares of the stock traded hands, compared to its average volume of 284,091. The stock has a 50-day moving average of $0.70 and a 200-day moving average of $0.73. The company has a market cap of $33.61 million, a price-to-earnings ratio of -0.98 and a beta of -0.06. Xilio Therapeutics has a one year low of $0.62 and a one year high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%.The firm had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.64 million. On average, research analysts predict that Xilio Therapeutics will post -1.14 EPS for the current fiscal year.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.